Valion Bio
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
47685 Lakeview Blvd. Ca, Fremont, Califo...Phone Number
(888) 276-6888Website
www.valionbio.comRevenue
-Stock Symbol
VBIOIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Valion Bio
Valion Bio is a late-stage biopharmaceutical company focused on developing biologic therapies that activate innate immune pathways for cytoprotection and immune modulation. The companys lead candidate, Entolimod, is a Toll-like receptor 5 agonist with a long development history, supported by regulatory designations such as FDA Fast Track and Orphan Drug status, and ongoing engagement with U.S. government agencies for potential inclusion in the Strategic National Stockpile. Valion Bio is also advancing Entolasta, a next-generation TLR5 agonist, while targeting applications in oncology supportive care, including neutropenia. In addition, its wholly owned subsidiary, Velocity Bioworks, operates as a contract development and manufacturing organization, supporting both internal production and third-party biotechnology clients.Explore more
Popular SearchesValion Bio IncTivic Health SystemsValion BioSIC Code 28,283NAICS Code 32,325Ticker NASDAQ: VBIOShow moreValion Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Valion Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Valion Bio had a recent Job posting/layoffs
Product Launch: Get notified when Valion Bio launches new products
Congratulate Masked Content for being promoted to Masked Content at Valion Bio
Earning: See what the market has to say on Valion Bio recently announced quarterly report
Check out if Valion Bio is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Valion Bio has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Valion Bio has new funding data
Valion Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Valion Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Valion Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Valion Bio.
Most Recent Scoops
Project
Product Development, Research & Development, Product Management, Intellectual Property, Legal Affairs, Contracts
New Hire
Executive Move
Executive Moves, New Hire
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Branding, Acquisitions, Mergers
Mergers & Acquisitions (M&A)
Valion Bio News & Media
Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures
Emanates from the FY27 NDAA process underway in the U.S. Congress Prioritizes radiation/nuclear countermeasures that are both prophylactic (radioprotectant) and therapeutic (radiomitigant) Follows Company's two recent briefings for senior DoW officials regarding its lead candidate,...VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME
Cross-Agency Discussion Highlights Interest in Oral Formulation as Field-Deployable Medical Countermeasure SAN ANTONIO, May 19, 2026 /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO), a late-stage innate immunotherapeutics company, today announced that it presented Entolimod for acute...Valion Bio Inc. (VBIO) Q1 2026 Earnings Call Prepared Remarks Transcript
Valion Bio Inc. (VBIO) Q1 2026 Earnings Call May 14, 2026 4:30 PM EDTCompany ParticipantsMichael Handley - CEO & DirectorLisa Wolf - CFO and Principal...Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform
First Commercial Installation Targeted for July 2026 in San Antonio; Strategic Reference Site Positions Velocity Bioworks at the Forefront of Next-Generation NMR-Based Diagnostics SAN ANTONIO, May 14, 2026 /PRNewswire/ -- Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq:...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Valion Bio
Sign Up For FreeTo access detailed company insights
Valion Bio is a late-stage biopharmaceutical company focused on developing biologic therapies that activate innate immune pathways for cytoprotection and immune modulation. The companys lead candidate, Entolimod, is a Toll-like receptor 5 agonist with a long development history, supported by regulatory designations such as FDA Fast Track and Orphan... Read More
